
# Neurodegenerative Disease





#### **Gloria Chiang, MD**

Assistant Professor, Division of Neuroradiology Weill Cornell Medical College / New York Presbyterian Hospital gcc9004@med.cornell.edu

# **GRANDMA's** been acting funny









#### Visit to Primary Care Physician:

Family:

"Forgetting things around the house"

"Dressing inappropriately"

"Crying spells"

Is this just old age
... or something else?




## Primary Care Physician:

- 1. History / Physical
  - other medical problems
- 2. Medications
- 3. Labs
- 4. Depression screen




## **Primary Care Physician:**

5. Imaging of the brain (MRI)- referral to neuroradiology




Neuroanatomy 101


#### Neuroanatomy:



## Neuroanatomy:





# **GRANDMA's** been acting funny



What could the Neuroradiologist see in the brain?

## Tumors = abnormal mass/growth = benign/malignant






Primary brain

Metastases

# Stroke = infarct = blood supply to brain cut off




# Trauma = hemorrhage = subdural, contusion







# Infection = abscess, meningitis




# Inflammation = demyelinating disease, multiple sclerosis



# **GRANDMA's** been acting funny




What did Grandma's brain MRI show?





- No tumor
- No infarct (stroke)
- No hemorrhage
- No infection
- No inflammation

+ Hippocampal atrophy





## Hippocampal atrophy

\* early site for Alzheimer's pathology postmortem

\* important in memory



## Alzheimer's disease prevalence

- 5% of people aged 70
- 20% aged 80
- 50% aged 90

## Neurodegenerative disease

= progressive degeneration and death of neurons



## Alzheimer's disease prevalence


- 5% of people aged 70
- 20% aged 80
- 50% aged 90

#### Differential:

- Frontotemporal dementia
- Diffuse Lewy Body dementia
- Vascular dementia
- Parkinson's dementia
- Normal pressure hydrocephalus
- \* atrophy pattern & symptoms




- quantitative methods



Sn 85%, Sp 88% for differentiating AD versus Normal aging Laakso, Neurobiol Aging 1998



- quantitative methods




Freesurfer
<a href="http://surfer.nmr.mgh.harvard.edu/">http://surfer.nmr.mgh.harvard.edu/</a>

Registration to an atlas; Segmentation into 70 regions - Requires computing power



- quantitative methods




## Quantitative whole-brain voxel-based morphometry

- 2000 Voxel-based Morphometry (VBM) – the methods (Ashburner, Friston)



- quantitative methods




VBM: Whole-brain statistical map (p<0.005 FDR)

Whitwell JL. J of Neurosci 2009; 29: 9661-9664.



- quantitative methods




Arterial Spin Labeling (ASL) MR Perfusion:

- higher inter-rater reliability than SPGR. Sn 85%, Acc 70%

Raji CA et al. AJNR 2010; 31: 847-855. [units of ml blood/g tissue/min]



- quantitative methods




Zhang Y et al. Neurology 2007; 68: 13-19.

Diffusion Tensor Imaging (DTI) accuracy (NL vs AD): 78 → 91%

Zhang Y et al. Brain 2009; 132: 2579-2592.



- quantitative methods





Resting State Function MRI (rsfMRI): AD vs NL
Default mode network (decreased) vs Executive network (increased)

Agosta F et al. Neurobiol Aging 2012; 33: 1564-1578



- quantitative methods





GLUCOSE METABOLISM FDG-PET

AMYLOID DEPOSITION PET-PiB

# Alzheimer's pathogenesis 1906-now

## Amyloid cascade hypothesis

(Hardy, Allsop, Selkoe 1991)

\*\*Beta-amyloid plaques\*\*

Neurofibrillary tangles (tau)

Neuronal degeneration (MRI)

Memory dysfunction (MCI)

Clinical dysfunction (Alzheimer's Disease)




- No known therapy to slow progression of disease
- <u>Donepezil</u> (Aricept) provides
   symptomatic relief (memory, behavior)





- No known therapy to slow progression of disease
- Targeting amyloid?

Monoclonal antibodies against beta-amyloid





- No known therapy to slow progression of disease
- Treating other risk factors?

# THE LANCET Neurology



The projected effect of risk factor reduction on Alzheimer's disease prevalence

Dr Deborah E Barnes, PhD , Prof Kristine Yaffe, MD

Published Online: 19 July 2011



- No known therapy to slow progression of disease
- Treating other risk factors?

## THE LANCET Neurology

Review

The projected effect of risk factor reduction on Alzheimer's disease prevalence

Dr Deborah E Barnes, PhD → Prof Kristine Yaffe, MD
Published Online: 19 July 2011

#### 50% Alzheimer's cases attributable to modifiable risk factors:

- physical inactivity/obesity, hypertension, diabetes, smoking



## Quantitative imaging

- diagnosis
- monitoring progression

